OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX) in a research note released on Wednesday. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research note on Wednesday, November 13th.

OncoCyte Stock Performance

NASDAQ:OCX opened at $2.75 on Wednesday. The stock’s 50 day moving average price is $2.99 and its 200 day moving average price is $2.98. OncoCyte has a 52-week low of $2.29 and a 52-week high of $4.34.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.54). The firm had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. During the same quarter in the previous year, the company earned ($0.57) EPS.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, CFO Andrea S. James purchased 33,670 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, with a total value of $99,999.90. Following the acquisition, the chief financial officer now directly owns 33,670 shares of the company’s stock, valued at $99,999.90. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This trade represents a 26.69 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 1.58% of the company’s stock.

Institutional Trading of OncoCyte

An institutional investor recently raised its position in OncoCyte stock. Geode Capital Management LLC grew its holdings in OncoCyte Co. (NASDAQ:OCX) by 12.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,980 shares of the company’s stock after buying an additional 11,289 shares during the quarter. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 at the end of the most recent quarter. Institutional investors and hedge funds own 55.35% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.